Identiv (NASDAQ:INVE) reported quarterly sales of $29.00 million which beat the analyst consensus estimate of $27.87 million by 4.06 percent. This is a 1.70 percent increase over sales of $28.52 million the same period last year.
Graphite Bio Announces Voluntary Pause Of Phase 1/2 CEDAR Study Of nulabeglogene autogedtemcel For Sickle Cell Disease
Graphite Bio, Inc. (NASDAQ:GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first